About

This talk will discuss the basics of pancreaticobiliary malignancy, in particular pancreatic cancer. Pancreatic cancer is a very aggressive form of cancer, with an overall five-year survival rate as low as approximately 10%. The incidence of this cancer is increasing worldwide. An understanding of the clinical presentation, diagnostic and staging investigations, initial management, and systemic and surgical treatment is important for any junior doctor.

This session aims to build the confidence of senior medical students and Foundation Year 1 Doctors to enable them to better appreciate this disease and understand the patient's journey. It will also provide an overview of the staging and the current modalities of treatment available to manage this type of cancer.

Suitable for:

• Medical Students (clinical years))
• Foundation Year 1 Doctors

Speaker:

Mr Nigel Jamieson
Consultant HPB Surgeon
Glasgow Royal Infirmary, Glasgow

Mr Nigel Jamieson is a Consultant HPB Surgeon at Glasgow Royal Infirmary, Glasgow and a Clinical Senior Lecturer within the Institute of Cancer Sciences, University of Glasgow. His PhD, which was funded by the Chief Scientist Office, explored gene expression signatures in pancreatic adenocarcinoma. He completed observerships at Johns Hopkins, Baltimore and an international fellowship year of pancreas and liver surgery in Royal North Shore Hospital, Sydney, Australia. He was awarded a Clinician Scientist Fellowship by Cancer Research UK, as well as a Lord Kelvin and Adam Smith Leadership Fellowship from the University of Glasgow.

Mr Jamieson has contributed to over 100 peer reviewed publications and, with an active role in the development and management of the Precision-Panc platform, his Laboratory Research Group’s focus is on the interaction between the immune microenvironment and chemotherapy in the tumours of patients with pancreatic cancer, as well as spatial transcriptomic characterisation of HPB malignancies and premalignant lesions. He works closely with Pancreatic Cancer UK and is part of a national group that aims to standardise care for patients with pancreatic cancer across the UK.